Price
$3.19
Increased by +4.59%
Dollar volume (20D)
39.29 K
ADR%
6.57
Earnings report date
Nov 7, 2024
Shares float
6.03 M
Shares short
203.08 K [3.37%]
Shares outstanding
13.37 M
Market cap
40.77 M
Beta
1.01
Price/earnings
N/A
20D range
2.84 3.34
50D range
2.59 3.48
200D range
2.29 4.34

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.

The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.

The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents.

OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 8, 24 -0.36
Increased by +66.36%
-0.56
Increased by +35.71%
Apr 12, 24 -2.12
Decreased by -10.70 K%
-1.14
Decreased by -85.96%
Dec 31, 23 -2.12
Decreased by -430.00%
-1.14
Decreased by -85.96%
Nov 9, 23 -0.81
Decreased by -912.50%
-1.01
Increased by +19.80%
Aug 10, 23 -1.07
Decreased by -1.43 K%
-0.87
Decreased by -22.99%
May 11, 23 0.02
Increased by +118.18%
-0.08
Increased by +125.00%
Mar 31, 23 -0.40
Decreased by -233.33%
-0.09
Decreased by -344.44%
Nov 10, 22 -0.08
Increased by +46.67%
-0.11
Increased by +27.27%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 24 104.00 K
Decreased by -77.54%
-4.53 M
Increased by +45.64%
Decreased by -4.36 K%
Decreased by -142.02%
Mar 31, 24 176.00 K
Decreased by -40.74%
-9.13 M
Increased by +79.86%
Decreased by -5.19 K%
Increased by +66.02%
Dec 31, 23 314.00 K
Increased by +14.60%
-15.99 M
Increased by +64.44%
Decreased by -5.09 K%
Increased by +68.97%
Sep 30, 23 429.00 K
Increased by +540.30%
-6.49 M
Increased by +31.30%
Decreased by -1.51 K%
Increased by +89.27%
Jun 30, 23 463.00 K
Increased by +95.36%
-8.33 M
Decreased by -3.67%
Decreased by -1.80 K%
Increased by +46.93%
Mar 31, 23 297.00 K
Decreased by -21.84%
-45.34 M
Decreased by -324.21%
Decreased by -15.26 K%
Decreased by -442.76%
Dec 31, 22 274.00 K
Decreased by -92.37%
-44.98 M
Decreased by -25.34%
Decreased by -16.42 K%
Decreased by -1.54 K%
Sep 30, 22 67.00 K
Decreased by -93.19%
-9.45 M
Increased by +31.56%
Decreased by -14.10 K%
Decreased by -905.18%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY